Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenalidomide + recombinant human erythropoietin
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral (lenalidomide), Subcutaneous (recombinant Human Erythropoietin), Intravenous (recombinant Human Erythropoietin)
01
Overview
A combination therapy of **lenalidomide**, an immunomodulatory small molecule and thalidomide analogue, and **recombinant human erythropoietin (epoetin alfa or beta)**, a biologic erythropoiesis-stimulating agent (ESA), used primarily in lower-risk, non-del(5q) myelodysplastic syndrome (MDS) patients with anemia resistant to ESAs. Lenalidomide modulates the immune system, inhibits angiogenesis, and promotes malignant cell apoptosis, while also augmenting erythropoietin receptor signaling. Recombinant human erythropoietin directly stimulates erythropoiesis by binding and activating the erythropoietin receptor. The combination results in superior **erythroid response rates** and durability compared to lenalidomide monotherapy in this population[1][2][3][4][6].
- Brand names
- Revlimid (for lenalidomide)Lenalidomide AccordLenalidomide KrkaLenalidomide MylanEpoetin Alfa (for recombinant human erythropoietin)Erythropoietin beta (for recombinant human erythropoietin)
- Other names
- LEN + EPOlenalidomide + epoetin alfalenalidomide + erythropoietin betalenalidomide + rhu-EPO
02
Targets
CK1α (Casein kinase I alpha)CRBN (Cereblon)Erythropoietin ReceptorIKZF1 (Ikaros family zinc finger protein 1)IKZF3 (Zinc finger protein Aiolos)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on lenalidomide + recombinant human erythropoietin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenalidomide + recombinant human erythropoietin.